Tirzepatide
2.5–15 mg · Weekly
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 3 cited sources
Evidence
- Human Studies
- 20
- Animal Studies
- 25
- Clinical Status
- FDA Approved
- Confidence
- High
- Long-Term Safety
- Well-established for the approved product through trials and growing post-approval data; compounded versions are not equivalent
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A dual GLP-1/GIP receptor agonist studied in large Phase 3 trials (the SURPASS and SURMOUNT programs) and FDA-approved under the brand names Mounjaro (diabetes) and Zepbound (chronic weight management). Trial data generally shows larger average weight loss than semaglutide.
Common Protocols
- Weekly subcutaneous injection, titrated up over months per approved labeling
Side Effects
- GI side effects (nausea, diarrhea, vomiting, constipation) are common and generally dose-dependent
- Same class warnings as other GLP-1/GIP drugs: pancreatitis, gallbladder issues, thyroid C-cell tumor warning from animal studies
Interactions
- May slow absorption of oral medications due to delayed gastric emptying
Practical Details
- Cost
- $$$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution (compounded); manufactured pens per label instructions
Key Studies & Reviews
- Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. PMID 35658024.
- Jastreboff AM et al. (2025). Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. PMID 39536238.
- Nong K et al. (2026). Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. PMID 42419792.
Search the Research
Tirzepatide FAQ
What is the typical Tirzepatide dosage?
Commonly reported protocols: Weekly subcutaneous injection, titrated up over months per approved labeling. Our reference entry uses 2.5–15 mg, Weekly. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of Tirzepatide?
Reported side effects include: GI side effects (nausea, diarrhea, vomiting, constipation) are common and generally dose-dependent; Same class warnings as other GLP-1/GIP drugs: pancreatitis, gallbladder issues, thyroid C-cell tumor warning from animal studies.
Is Tirzepatide FDA approved?
Tirzepatide is FDA-approved for specific medical indications (described in the summary above). Use for anything else is off-label and should be supervised by a prescriber.
How much research is there on Tirzepatide?
Our evidence profile counts roughly 20 human and 25 animal studies, with high overall confidence. Long-term safety: Well-established for the approved product through trials and growing post-approval data; compounded versions are not equivalent.
Does Tirzepatide interact with other drugs or supplements?
May slow absorption of oral medications due to delayed gastric emptying.
How do I reconstitute Tirzepatide?
A common setup is a 10 mg vial mixed with 2 mL of bacteriostatic water, which puts a 2.5–15 mg dose at about 25 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution (compounded); manufactured pens per label instructions.
Compare
Related compounds
GLP-1/GIP dual agonist; superior weight loss